Will a magenta first reviewproduct be born? More than 3 billion antimicrobial faucets are expected to add new products.

Pharmaceutical Network July 29 - Recently, Guangzhou Magenta Pharmaceuticals' hydrochloride klinmycin capsules entered the "in the approval" state, is expected to be approved in the near future, the product is expected to become a magenta first rated products.sales of Klinmycin at the end of China's public medical institutions has exceeded 3 billion yuan, as the leading enterprise of the variety, the approval of new products is expected to once again enhance the company's market position.Figure 1: Review of a magentachlor cline capsule Source: MED China Drug Review Database 2.0 Figure 2: 2019 Klinmycin's Enterprise Competition Source: China's public medical institutions Terminal Competition Pattern SinneNet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public health institutions) terminal Klinmycin sales of more than 3 billion yuan.'s market share of a magenta company rose from 17.93 percent in 2015 to 22.62 percent in 2019, with the main products being the clindamycin-clindamycin palmacid dispersant tablets, the chlorinate palmate particles, and the injection of klinmycin.at present, a magenta submitted four products of the consistency evaluation supplementary applications are in the review and approval, including injection of ozagre sodium, injection with axiovir, hydrochloric acid micro-carbide tablets and injection of omeprazole sodium, if this hydrochloric acid klinmycin capsule can be successfully approved, according to the new classification of the same evaluation, will become the first evaluation products of the enterprise.Source: The statistics of the internal database review data as of 28 July 2020, if there are any errors, please indicate..